Publications by authors named "Vincent Nicolai"
Article Synopsis
- Following the IMpassion130 trial, France launched an early access program allowing patients with PD-L1-positive advanced triple negative breast cancer to receive a combo of paclitaxel and atezolizumab, but it was discontinued after the negative IMpassion131 trial results.
- A multicentric analysis of 64 patients enrolled in the EAP showed a median progression-free survival of 4.1 months and overall survival of 17.9 months, with 28% having a positive response at 6 months.
- The use of corticosteroids before treatment was identified as a negative factor affecting progression-free survival, while no new safety signals were detected in this real-world study.
Purpose: Data about incidence, biological, and clinical characteristics of oligometastatic breast cancer (OMBC) are scarce. However, these data are essential in determining optimal treatment strategy. Gaining knowledge of these elements means observing and describing large, recent, and consecutive series of OMBC in their natural history.
View Article and Find Full Text PDFArticle Synopsis
- * A new 67-gene expression prognostic signature called CINSARC has been developed, which has shown effectiveness in predicting outcomes across various cancers and can be used on preserved tissue samples through NanoString® technology.
- * In studies of CRC patients, CINSARC effectively differentiated between groups with different survival rates, demonstrating strong prognostic capacity that surpasses traditional TNM staging and CMS classification, making it a valuable tool for clinical practice.
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant setting. Our study aimed to analyse the efficacy of taxane rechallenge in case of early metastatic relapse in a multicentre retrospective observational study compared with other chemotherapies.
Methods: We analysed the French national ESME metastatic BC (MBC) database and selected HER2- MBC patients who received CT in first-line treatment for a metastatic relapse occurring 3-24 months after previous (neo)adjuvant taxanes treatment.
Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a median of 15 to 18 months. These tumors have long suffered from a purely negative definition, but the last few years have witnessed many breakthrough genomic and molecular findings, that could dramatically improve our understanding of the biological heterogeneity of TNBC. Moreover, based on these genomic analyses, new generation of clinical trials, using many innovative therapies directed against novel targets, had been conducted.
View Article and Find Full Text PDF